Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565–1570 (2011).
  Medline CASGoogle Scholar
• 2 Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010). •• Phase III trial showing anti-CTLA-4 therapy offers durable responses in metastatic melanoma.
  Medline CASGoogle Scholar
• 3 Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532 (2015). •• Phase III trial comparing pembrolizumab to ipilimumab in metastatic melanoma.
  Medline CASGoogle Scholar
• 4 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320–330 (2015). •• Phase III trial comparing nivolumab to ipilimumab in metastatic melanoma.
  Medline CASGoogle Scholar
• 5 Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol. 23, 515–548 (2005).
  MedlineGoogle Scholar
• 6 Carter L, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol. 32(3), 634–643 (2002).
  Medline CASGoogle Scholar
• 7 Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793–800 (2002).
  Medline CASGoogle Scholar
• 8 Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4(127), 127ra137 (2012).
  Google Scholar
• 9 Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 75(11), 2139–2145 (2015).
  Medline CASGoogle Scholar
• 10 Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 56(8), 1173–1182 (2007).
  Medline CASGoogle Scholar
• 11 Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28(3), 682–688 (2011).
  Medline CASGoogle Scholar
• 12 Nomi T, Sho M, Akahori T et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13(7), 2151–2157 (2007).
  Medline CASGoogle Scholar
• 13 Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol. 2012, 656340 (2012).
  MedlineGoogle Scholar
• 14 Rosenwald A, Wright G, Leroy K et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198(6), 851–862 (2003).
  Medline CASGoogle Scholar
• 15 Lyford-Pike S, Peng S, Young GD et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73(6), 1733–1741 (2013).
  Medline CASGoogle Scholar
• 16 Chow LQ, Burtness B, Weiss J et al. A Phase Ib study of pembrolizumab in patients with human papilloma virus (HPV)-positive and negative head and neck cancer. Presented at: European Society for Medical Oncology (ESMO) 2014 Congress. Madrid, Spain, 26–30 September 2014.
  Google Scholar
• 17 Seiwert TY, Haddad RI, Gupta S et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May–2 June 2015.
  Google Scholar
• 18 Segal NH, Antonia SJ, Brahmer JR et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 19 Berghoff AS, Kiesel B, Widhalm G et al. PD1 and PD-L1 expression in glioblastoma. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 20 Sampson JH, Vlahovic G, Sahebjam S et al. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May–2 June 2015.
  Google Scholar
• 21 Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507(7492), 315–322 (2014).
  Medline CASGoogle Scholar
• 22 Bellmunt JP, Powles DP, Braiteh T et al. Inhinition of PD-L1 by MPDL3280A leads to clinical activity in pts with metastatic urothelial bladder cancer (UBC). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 23 Petrylak DP, Powles T, Bellmunt J et al. A Phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May–2 June 2015.
  Google Scholar
• 24 Bellmunt J, Berger R, Montgomery B et al. Phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (pts) with advanced urothelial tract cancer. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 25 Leite KR, Reis ST, Junior JP et al. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn. Pathol. 10, 189 (2015).
  MedlineGoogle Scholar
• 26 Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin. Cancer Res. 13(2 Pt 2), s709–s715 (2007).
  Google Scholar
• 27 Shin SJ, Jeon YK, Kim PJ et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann. Surg. Oncol. (2015) (Epub ahead of print).
  Google Scholar
• 28 Joseph RW, Millis SZ, Carballido EM et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol. Res. 3(12), 1303–1307 (2015).
  Medline CASGoogle Scholar
• 29 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012). •• First large trial targeting PD-1 in cancer.
  Medline CASGoogle Scholar
• 30 Motzer RJ, Rini BI, McDermott DF et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol. 33(13), 1430–1437 (2015). •• Phase III trial comparing nivolumab to everolimus in advanced renal cell carcinoma.
  Medline CASGoogle Scholar
• 31 Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
  Medline CASGoogle Scholar
• 32 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012). •• First large trial targeting PD-L1 in cancer.
  Medline CASGoogle Scholar
• 33 Hammers HJ, Plimack ER, Infante JR et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.
  Google Scholar
• 34 Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  Medline CASGoogle Scholar
• 35 Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813–1821 (2013).
  Medline CASGoogle Scholar
• 36 Kwon ED, Drake CG, Scher HI et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184–043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700–712 (2014).
  Medline CASGoogle Scholar
• 37 Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 67(5), 1883–1886 (2007).
  Medline CASGoogle Scholar
• 38 Pages F, Kirilovsky A, Mlecnik B et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27(35), 5944–5951 (2009).
  Medline CASGoogle Scholar
• 39 Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960–1964 (2006).
  Medline CASGoogle Scholar
• 40 Galon J, Pages F, Marincola FM et al. Cancer classification using the Immunoscore: a worldwide task force. J. Translat. Med. 10, 205 (2012).
  MedlineGoogle Scholar
• 41 Galon J, Mlecnik B, Bindea G et al. toward the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232(2), 199–209 (2014).
  Medline CASGoogle Scholar
• 42 Nagorsen D, Keilholz U, Rivoltini L et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 60(17), 4850–4854 (2000).
  Medline CASGoogle Scholar
• 43 Droeser RA, Hirt C, Viehl CT et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur. J. Cancer 49(9), 2233–2242 (2013).
  Medline CASGoogle Scholar
• 44 Lipson EJ, Sharfman WH, Drake CG et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19(2), 462–468 (2013).
  Medline CASGoogle Scholar
• 45 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
  Medline CASGoogle Scholar
• 46 Shinto E, Hase K, Hashiguchi Y et al. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer. Ann. Surg. Oncol. 21(Suppl. 3), S414–S421 (2014).
  MedlineGoogle Scholar
• 47 Ott PA, Piha-Paul SA, Munster P et al. Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. Presented at: The European Cancer Congress (ECC 2015). Vienna, Austria, 25–29 September 2015.
  Google Scholar
• 48 Protti MP, De Monte L. Immune infiltrates as predictive markers of survival in pancreatic cancer patients. Front. Physiol. 4, 210 (2013).
  MedlineGoogle Scholar
• 49 Ino Y, Yamazaki-Itoh R, Shimada K et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 108(4), 914–923 (2013).
  Medline CASGoogle Scholar
• 50 Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin. Cancer Res. 18(16), 4266–4276 (2012).
  Medline CASGoogle Scholar
• 51 Loos M, Hedderich DM, Ottenhausen M et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC cancer 9, 463 (2009).
  MedlineGoogle Scholar
• 52 Goeppert B, Frauenschuh L, Zucknick M et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 109(10), 2665–2674 (2013).
  Medline CASGoogle Scholar
• 53 Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344(6184), 641–645 (2014).
  Medline CASGoogle Scholar
• 54 Ye Y, Zhou L, Xie X, Jiang G, Xie H, Zheng S. Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J. Surg. Oncol. 100(6), 500–504 (2009).
  MedlineGoogle Scholar
• 55 Fu J, Xu D, Liu Z et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328–2339 (2007).
  MedlineGoogle Scholar
• 56 Gao Q, Qiu SJ, Fan J et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25(18), 2586–2593 (2007).
  MedlineGoogle Scholar
• 57 Hoechst B, Voigtlaender T, Ormandy L et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50(3), 799–807 (2009).
  Medline CASGoogle Scholar
• 58 Gao Q, Wang XY, Qiu SJ et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin. Cancer Res. 15(3), 971–979 (2009).
  Medline CASGoogle Scholar
• 59 El-Khoueiry ABMI, Crocenzi TS, Hobart WT et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209–040. Presented at: ASCO Annual Meeting 2015. Chicago, IL, USA, 29 May–2 June 2015.
  Google Scholar
• 60 Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J. Surg. Oncol. 107(5), 517–522 (2013).
  Medline CASGoogle Scholar
• 61 Lu B, Chen L, Liu L et al. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. Immunol. Res. 50(2–3), 269–275 (2011).
  Medline CASGoogle Scholar
• 62 Zheng Z, Bu Z, Liu X et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin. J. Cancer Res. 26(1), 104–111 (2014).
  MedlineGoogle Scholar
• 63 Eto S, Yoshikawa K, Nishi M et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 64 Ohigashi Y, Sho M, Yamada Y et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11(8), 2947–2953 (2005).
  Medline CASGoogle Scholar
• 65 Eto S, Iwata T, Yoshikawa K et al. Relationship of programmed death 1 (PD-1) expression to the recurrence in gastric cancer. Presented at: 2015 Gastrointestinal Cancers Symposium (ASCO GI). San Francisco, CA, 15–17 January 2015.
  Google Scholar
• 66 Muro K, Bang Y-J, Shankaran V et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Presented at: 2015 Gastrointestinal Cancers Symposium (ASCO GI). San Francisco, CA, 15–17 January 2015.
  Google Scholar
• 67 Shankaran V, Muro K, Bang Y-J et al. Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). Presented at: 2015 Gastrointestinal Cancers Symposium (ASCO GI). San Francisco, CA, 15–17 January 2015.
  Google Scholar
• 68 Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563–567 (2014).
  Medline CASGoogle Scholar
• 69 Dieci MV, Criscitiello C, Goubar A et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann. Oncol. 25(3), 611–618 (2014).
  Medline CASGoogle Scholar
• 70 Ono M, Tsuda H, Shimizu C et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 132(3), 793–805 (2012).
  Medline CASGoogle Scholar
• 71 Ali HR, Provenzano E, Dawson SJ et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann. Oncol. 25(8), 1536–1543 (2014).
  Medline CASGoogle Scholar
• 72 Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28(1), 105–113 (2010).
  Medline CASGoogle Scholar
• 73 Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2(7), e24720 (2013).
  MedlineGoogle Scholar
• 74 Dushyanthen S, Beavis PA, Savas P et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 13, 202 (2015).
  MedlineGoogle Scholar
• 75 Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 139(3), 667–676 (2013).
  Medline CASGoogle Scholar
• 76 Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142–7147 (2011).
  Medline CASGoogle Scholar
• 77 Gatalica Z, Snyder C, Maney T et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol. Biomarkers Prev. 23(12), 2965–2970 (2014).
  Medline CASGoogle Scholar
• 78 Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2(4), 361–370 (2014).
  Medline CASGoogle Scholar
• 79 Barrett MT, Anderson KS, Lenkiewicz E et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6(28), 26483–26493 (2015).
  MedlineGoogle Scholar
• 80 Nanda RC, Laura Q, Dees EC, Berger R et al. A Phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Presented at: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, 9–13 December 2014.
  Google Scholar
• 81 Emens LAB, Cassier Fadi S, De Philippe Lord et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Presented at: Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, 9–13 December 2014.
  Google Scholar
• 82 Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 33(18), 2004–2012 (2015).
  Medline CASGoogle Scholar
• 83 Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015). •• Phase III trial comparing pembrolizumab to docetaxel in metastatic NSCLC.
  MedlineGoogle Scholar
• 84 Rizvi NA, Mazieres J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16(3), 257–265 (2015).
  Medline CASGoogle Scholar
• 85 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015). •• Phase III trial comparing nivolumab to docetaxel in metastatic squamous cell lung carcinoma.
  Medline CASGoogle Scholar
• 86 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
  Medline CASGoogle Scholar
• 87 Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet doi:10.1016/S0140-6736(15)01281-7 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 88 Horn L, Spigel DR, Gettinger SN et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a Phase Ia study. ASCO Meeting Abstracts 33(Suppl. 15), 8029 (2015).
  Google Scholar
• 89 Spira AI, Park K, Mazieres J et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). ASCO Meeting Abstracts 33(Suppl. 15), 8010 (2015).
  Google Scholar
• 90 Rizvi NA, Brahmer JR, Ou S-HI et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(Suppl. 15), 8032 (2015).
  Google Scholar
• 91 Gulley JL, Spigel D, Kelly K et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. ASCO Meeting Abstracts 33(Suppl. 15), 8034 (2015).
  Google Scholar
• 92 Rizvi NA, Antonia SJ, Chow LQM et al. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). ASCO Meeting Abstracts 31(Suppl. 15), 8072 (2013).
  Google Scholar
• 93 Antonia SJ, Brahmer JR, Gettinger S et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 90(5), S2 (2014).
  Google Scholar
• 94 Gettinger SN, Hellmann MD, Shepherd FA et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO Meeting Abstracts 33(Suppl. 15), 8025 (2015).
  Google Scholar
• 95 Papadimitrakopoulou V, Patnaik A, Borghaei H et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. ASCO Meeting Abstracts 33(Suppl. 15), 8031 (2015).
  Google Scholar
• 96 Antonia SJ, Gettinger S, Goldman J et al. Safety and efficacy of first-line nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 90(5), S32–S33 (2014).
  Google Scholar
• 97 Antonia SJ, Bendell JC, Taylor MH et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209–032. ASCO Meeting Abstracts 33(Suppl. 15), 7503 (2015).
  Google Scholar
• 98 Patnaik A, Socinski MA, Gubens MA et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. ASCO Meeting Abstracts 33(Suppl. 15), 8011 (2015).
  Google Scholar
• 99 Antonia SJ, Goldberg SB, Balmanoukian AS et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. ASCO Meeting Abstracts 33(Suppl. 15), 3014 (2015).
  Google Scholar
• 100 Liu SV, Powderly JD, Camidge DR et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(Suppl. 15), 8030 (2015).
  Google Scholar
• 101 Nghiem P, Bhatia S, Daud A et al. Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. Presented at: The European Cancer Congress (ECC 2015). Vienna, Austria, 25–29 September 2015.
  Google Scholar
• 102 Hubbard-Lucey VM, Tontonoz MJ. Translating science into survival: Report on the Inaugural International Cancer Immunotherapy Conference. Cancer Immunol. Res. 4, 3–11 (2016).
  Medline CASGoogle Scholar
• 103 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 104 Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568–571 (2014).
  Medline CASGoogle Scholar
• 105 Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 348(6230), 69–74 (2015).
  Medline CASGoogle Scholar